Pamela Lopez, APRN
Family · Weslaco, TXNPI 1952474397
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,908 of the $21,899 with a category attached, or 86.3%. It is spread thinly across 39 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 690 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mannkind Corporation$4K
- Novo Nordisk$3K
- Dexcom, Inc.$2K
- Corcept Therapeutics$2K
- Lilly USA, LLC$2K
- Amgen$2K
- plus $8K from 33 others
What the payments were for
- Consulting fees$7964%
- Travel & lodging$2,09010%
- Food & beverage$18,90886%
- Education$200%
- Gifts$590%
- Entertainment$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$3,204
- Ozempic$927
- Korlym$667
- DEXCOM G6 TRANSMITTER$593
- FreeStyle Libre$532
- EVERSENSE E3 SENSOR KIT - RETAIL$352
- Pogo Automatic Blood Glucose Monitoring System$250
- MOUNJARO$228
- Wegovy$227
- RYBELSUS$227
- DEXCOM G7 GSS (161)$216
- Kerendia$150
- REZDIFFRA$150
- EVENITY$142
- Prolia$142
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$138
- Omnipod$129
- JARDIANCE$122
- t:slim X2 Insulin Pump with Control-IQ$122
- VOQUEZNA$120
How this compares
$21,899 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 881 | $1,365,709 |
| KorlymMifepristone | 26 | $979,215 |
| OzempicSemaglutide | 349 | $577,806 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 307 | $370,990 |
| JardianceEmpagliflozin | 244 | $339,037 |
| Tresiba Flextouch U-200Insulin Degludec | 380 | $331,299 |
| TrulicityDulaglutide | 91 | $163,923 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 59 | $128,865 |
| FarxigaDapagliflozin Propanediol | 93 | $95,324 |
| LinzessLinaclotide | 86 | $82,132 |
| Xigduo XrDapaglifloz Propaned/Metformin | 74 | $81,557 |
| KerendiaFinerenone | 71 | $80,105 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $71,506 |
| TradjentaLinagliptin | 58 | $65,960 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 65 | $60,795 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,665 | $1,534,584989 claims |
| Corcept TherapeuticsKorlym | $1,745 | $979,21526 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Trijardy Xr, Synjardy | $324 | $850,781681 claims |
| Novo NordiskOzempic, Rybelsus | $2,806 | $607,697360 claims |
| AstraZenecaFarxiga | $312 | $95,32493 claims |
| AbbVieLinzess | $126 | $82,13286 claims |
| BayerKerendia | $417 | $80,10571 claims |
| AmgenEvenity (2 Syringes) | $1,635 | $53,21516 claims |
| Mannkind CorporationAfrezza | $4,125 | $35,58316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in Weslaco
- David WeirDallas$959K
- Robin BeachHouston$428K
- April LopezMcAllen$417K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
- Angela AchaPflugerville$174K
- Susan BowlinIrving$164K
- Stephanie RodriguezCorpus Christi$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.